Last Updated : May 22, 2024
Details
Project Status:
Active
Project Line:
Health Technology Review
Project Sub Line:
Technology Review
Project Number:
HC0082-000
Expected finish date:
Renal cell carcinoma (RCC) is the most common type of renal cancer. Over the past 10 years, the treatment options have evolved substantially — in addition to mammalian target of rapamycin inhibitors, tyrosine kinase inhibitors of vascular endothelial growth factor receptors and immune checkpoint inhibitors have also been introduced. However, there is currently a paucity of real-world evidence on how these options are used and how long patients typically stay on various treatments. In this study, we will conduct a treatment pattern analysis to identify the sequence of treatments for patients with RCC who started first-line publicly funded renal cancer treatments. The results from this study will help inform discussions on system and resource planning, and potentially prompt future analyses relating to RCC treatments in Canada.
Last Updated : May 22, 2024